Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …

To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …

Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shedding was
observed from the upper respiratory tract of a female immunocompromised individual with …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Background There is uncertainty about the impact of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection in individuals with rare inborn errors of immunity (IEI) …

Mass SARS-Cov-2 vaccination campaign represents the only strategy to defeat the global
pandemic we are facing. Immunocompromised patients represent a vulnerable population at …

The response to the coronavirus disease 2019 (COVID-19) pandemic has been hampered
by lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging
infectious diseases; its efficacy was later associated with the evidence that polyclonal …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 160
million infections and more than 3 million deaths worldwide. Although effective vaccines are …

In the absence of effective countermeasures, human convalescent plasma has been widely
used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel …